LifeSpan Bio acquires Everest Biotech to expand reagent portfolio
Category: #health  By Mateen Dalal  Date: 2019-07-17
  • share
  • Twitter
  • Facebook
  • LinkedIn

LifeSpan Bio acquires Everest Biotech to expand reagent portfolio

The transaction will be LifeSpan BioSciences’ second investment this year following its Nordic-MUbio acquisition

LifeSpan BioSciences (LSBio), a provider of life science research reagents and antibodies, has recently announced that it has acquired Everest Biotech, a certified expert in antigen polyclonal antibodies. The acquisition  will help LifeSpan BioSciences expand its product offering and strengthen its position as the fastest growing provider in the market for research reagent.

LSBio, though this partnership, will offer a comprehensive reagents catalogue which can be combined with the wide range of IHC validated primary antibodies.

Heather Holemon, LSBio’s CEO said that the company is looking forward to adding the product range produced by Everest Biotech to its portfolio. The offerings by Everest Biotech stand out owing to their exceptional high quality, which will perfectly complement LSBio’s existing portfolio.

Citing reliable sources, Everest Biotech is committed towards continuous improvement and quality that has ensured the growth of the company’s catalogue. It now has scores of goat antibodies against a wide range of mouse, rat and human targets in the biomedical space.

LSBio’s offering of more than 500,000 polyclonal and monoclonal primary antibodies will expand to include all protein in the proteome after the acquisition. Over 15,000 antibodies of LSBio have been identified as IHC reagents that are exceptional and have been given the IHC-plus brand through the extensive in-house testing.

Apparently, after LSBio acquired Nordic-MUbio in February, the Everest Bio acquisition will mark the second investment made by the company this year.

For the uninitiated, LifeSpan BioSciences, Inc. provides IHC validated reagent antibodies along with services to the global community of pharmaceutical, biotech and academic researchers and has been a leader in the industry after its inception in 1995.

The company has built a catalogue that contains over 750,000 antibodies, proteins, biochemicals and assay kits which it sells through the network of its international distributors.

 

Source Credit-https://finance.yahoo.com/news/lifespan-biosciences-announces-acquisition-everest-080000460.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

UAE extends travel ban for Indians amid strict COVID-19 guidelines
UAE extends travel ban for Indians amid strict COVID-19 guidelines
By Mateen Dalal

United Arab Emirates (UAE) has reportedly extended travel ban for individuals travelling from India and several other south Asian countries on the pretext of COVID-19 guidelines. As reported by Etihad Airlines, the ban will be followed till 31st July...

Adevinta Ventures backs Lovys's Series A follow-on investment round
Adevinta Ventures backs Lovys's Series A follow-on investment round
By Mateen Dalal

Adevinta Ventures, an investment arm of Adevinta, has announced its investment in French insurance service provider ‘Lovys’, marking as its first investment in France in the Fintech and Insurtech sector. With this investment, Adevinta Ve...

Indian EV startup eBikeGo expands fleet to 2,100, hires 70 employees
Indian EV startup eBikeGo expands fleet to 2,100, hires 70 employees
By Mateen Dalal

The company is aiming for achieving a 2% share in the Indian electric two-wheeler market, with plans to deploy 200,000 e-scooters across 100 cities eBikeGo, an electric vehicle startup, has recently revealed that it has increased its fleet of electr...